Immunoglobulin A nephropathy (IgAN or IgA nephropathy), also known as \u00a0\u00a0 \u00a0Berger\u2019s disease, is a rare autoimmune condition that damages the glomeruli inside the kidneys. Initial treatment of IgAN predominantly comprises RAAS \u00a0\u00a0 \u00a0inhibitors, SGLT-2 inhibitors, immunosuppressants, and\/or diuretics. The FDA\u2019s acceptance of a surrogate clinical trial endpoint\u2014reduction in proteinuria\u2014has enabled the accelerated approval of novel IgAN therapies and the potential for the rapid evolution of the therapeutic landscape. Under this scheme, the FDA approved Calliditas Therapeutics\u2019 Tarpeyo (delayed-release budesonide; now fully approved) and Travere Therapeutics\u2019 Filspari (sparsentan). This report closely examines how the key established and newly launched immunosuppressive and non-immunosuppressive therapies are being used to treat newly diagnosed and recently treated IgAN patients.
\n* How have Tarpeyo and Filspari been integrated into the treatment algorithm, and in what line of therapy are they usually prescribed to new\u00a0\u00a0 \u00a0patients?
\n* What shares do key therapies and brands garner by line of therapy in newlydiagnosed IgAN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IgAN patients?\u00a0
\n* What percentage of IgAN patients receive drug therapy within one year of\u00a0
\n* What percentage of IgAN patients are treated with monotherapy vs. combination therapy?\u00a0
\n* What proportion of patients add Farxiga (dapagliflozin) to their ongoing\u00a0\u00a0 \u00a0RAAS inhibitor therapy? What proportion of patients switch to Tarpeyo?\u00a0
\nWhat are the product-level compliance and persistency rates among\u00a0<\/p>\n
*Markets covered:* United States*Key companies:* Calliditas Therapeutics, Travere Therapeutics, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson\u00a0\u00a0 \u00a0*Key drugs:* RAAS inhibitors, corticosteroids, Tarpeyo (budesonide \u00a0\u00a0 \u00a0delayed-release), Filspari (sparsentan), SGLT-2 inhibitors (Jardiance, Farxiga, Invokana)<\/p>\n
*Product description*\u00a0\u00a0 \u00a0\/Treatment Algorithms: Claims Data Analysis\/ provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and\u00a0\u00a0 \u00a0overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-413447","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413447\/revisions"}],"predecessor-version":[{"id":575988,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413447\/revisions\/575988"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=413447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}